Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Infections predict death in diffuse large B cell lymphoma

16 Jul 2017
GIS, CSI make first collaborative discovery on cancer progression

Diffuse large B cell lymphoma (DLBCL) patients with neutropenia and multiple comorbidities have a high risk of death and infection, a new study reports. Moreover, infection is an independent predictor of survival.

In a cohort of 325 DLBCL patients, Charlson Comorbidity Index (CCI) scores of 3 to 5 (hazard ratio [HR], 2.16; 95 percent CI, 1.71 to 2.74; p<0.001) and ≥6 (HR, 3.91; 2.34 to 6.28; p<0.001) were significantly correlated with infections.

Having Eastern Cooperative Oncology Group (ECOG) scores of 1 (HR, 2.09; 1.46 to 3.01; p<0.001), 2 (HR, 3.33; 2.22 to 5.04; p<0.001) and 3 (HR, 3.36; 1.99 to 5.66; p<0.001), and neutropenia within 48 hours (HR, 2.46; 1.91 to 3.17; p<0.001) were also associated with increased risks of infection.

Over the study duration of 10 years, 99 deaths (30.5 percent) were reported. The median time from diagnosis to death was 273 (129 to 636) days. The most common cause of death was progressive lymphoma (58.6 percent), followed by infection (12.1 percent) and other cancers (5.5 percent).

CCI scores of 3 to 5 (HR, 4.34; 2.00 to 6.33; p<0.001) and ≥6 (HR, 7.36; 3.38 to 16.00; p<0.001), an ECOG status of 1 (HR, 2.61; 1.02 to 6.66; p=0.045) and 3 or 4 (HR, 7.16; 2.04to 25.06; p=0.002), and infection upon admission (HR, 3.27; 2.03 to 5.27; p<0.001) were all independent and significant predictors of survival.

Participants were recruited from Monash Health I Melbourne, Australia, and were receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) or similar chemotherapies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.